Predictors of antibody persistence to the 7-valent pneumococcal conjugate vaccine in healthy Fijian infants at 12 months of age

Daniel E Lindholm; Paul V Licciardi; Felisita T Ratu; E Kim Mulholland; Cattram D Nguyen; Fiona M Russell

doi:10.1016/j.vaccine.2020.06.025

Predictors of antibody persistence to the 7-valent pneumococcal conjugate vaccine in healthy Fijian infants at 12 months of age

Vaccine. 2020 Jul 14;38(33):5095-5099. doi: 10.1016/j.vaccine.2020.06.025. Epub 2020 Jun 21.

Authors

Daniel E Lindholm¹, Paul V Licciardi¹, Felisita T Ratu², E Kim Mulholland³, Cattram D Nguyen⁴, Fiona M Russell⁵

Affiliations

¹ Infection and Immunity, Murdoch Children's Research Institute (MCRI), Melbourne, Australia; Centre for International Child Health, Department of Paediatrics, The University of Melbourne, Australia.
² Infection and Immunity, Murdoch Children's Research Institute (MCRI), Melbourne, Australia.
³ Infection and Immunity, Murdoch Children's Research Institute (MCRI), Melbourne, Australia; London School of Hygiene and Tropical Medicine, London, UK.
⁴ Infection and Immunity, Murdoch Children's Research Institute (MCRI), Melbourne, Australia; Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Australia.
⁵ Infection and Immunity, Murdoch Children's Research Institute (MCRI), Melbourne, Australia; Centre for International Child Health, Department of Paediatrics, The University of Melbourne, Australia. Electronic address: fmruss@unimelb.edu.au.

PMID: 32580918
DOI: 10.1016/j.vaccine.2020.06.025

Abstract

Little is known about the predictors of antibody persistence to pneumococcal conjugate vaccines (PCV) in the context of reduced dose schedules. In Fiji, an RCT investigated 0, 1, 2 and 3 dose schedules of 7-valent PCV administered at 6, 10 and 14 weeks of age in 364 healthy infants. This study was a post-hoc analysis of the predictors of poor antibody persistence at 12 months, prior to a booster, using univariable and multivariable analyses. The strongest predictors of poor antibody persistence as measured by serotype-specific immunoglobulin G (IgG) and opsonophagocytosis (OI) assays were being of Indigenous Fijian ethnicity (IgG: adjusted odds ratio (aOR) 3.43, p < 0.001; OI: aOR 1.96, p = 0.013) and receipt of fewer than 3 doses of PCV. These findings may help to identify which children may be at an increased risk of pneumococcal disease in the context of reduced dose primary series PCV schedules.

Keywords: Ethnicity; Fiji; Infant; Pneumococcal conjugate vaccine; Poor antibody persistence; Reduced-dose schedule.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Bacterial
Fiji
Humans
Infant
Pneumococcal Infections* / prevention & control
Pneumococcal Vaccines*
Streptococcus pneumoniae
Vaccines, Conjugate

Substances

Antibodies, Bacterial
Pneumococcal Vaccines
Vaccines, Conjugate